Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 21%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is a highly promising biopharmaceutical firm with strong molecules such as cabozantinib and Cotellic, slated for further development and approval by mid-2026. With a solid 4 times increase in revenue to $610.8 million and a promising cash position of ~$1.43 billion in cash, cash equivalents and marketable securities, and plans to complete the $750 million stock repurchase program in May 2026, Exelixis can continue to deliver strong EPS growth rates for the coming years.

Bears say

Exelixis is facing financial struggles as evidenced by the impairment of long-lived assets in 2026 and the need for additional stock repurchase authorizations to provide EPS support. In addition, the upcoming catalysts highlighted may not be enough to offset the potential negative impact of decreased materiality in their ESG performance for investors.

Exelixis (EXEL) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 14 analysts, Exelixis (EXEL) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.